Premenstrual Dysphoric Disorder Awareness and Research Act of 2026

[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 8160 Introduced in House (IH)]

<DOC>

119th CONGRESS
  2d Session
                                H. R. 8160

To expand research, improve awareness, and increase access to treatment
 for individuals affected by Premenstrual Dysphoric Disorder, and for
                            other purposes.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             March 30, 2026

   Ms. Ansari (for herself, Mrs. Beatty, Mr. Bell, Ms. Brownley, Mr.
 Carter of Louisiana, Ms. Clarke of New York, Mr. Conaway, Mr. Goldman
  of New York, Mrs. Grijalva, Mr. Jackson of Illinois, Mr. Johnson of
Georgia, Mr. Kennedy of New York, Mr. Krishnamoorthi, Mr. McGarvey, Ms.
  Norton, Ms. Pressley, Ms. Ross, Mr. Thanedar, Ms. Tlaib, Mr. Tonko,
Mrs. Trahan, Ms. Velazquez, Ms. Williams of Georgia, and Ms. Wilson of
   Florida) introduced the following bill; which was referred to the
                    Committee on Energy and Commerce

_______________________________________________________________________

                                 A BILL

To expand research, improve awareness, and increase access to treatment
 for individuals affected by Premenstrual Dysphoric Disorder, and for
                            other purposes.

    Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Premenstrual Dysphoric Disorder
Awareness and Research Act of 2026''.

SEC. 2. FINDINGS.

    Congress finds the following:
            (1) Premenstrual Dysphoric Disorder (referred to in this
        section as ``PMDD'') is a severe, chronic, and often disabling
        medical condition affecting an estimated 5 to 8 percent of
        women and people assigned female at birth of reproductive age.
            (2) PMDD is characterized by extreme mood shifts,
        irritability, depression, anger, hopelessness, tension,
        anxiety, and physical symptoms, such as difficulty
        concentrating, change in appetite, decreased energy, over or
        under sleeping, or joint and muscle aches, in the luteal phase
        of the menstrual cycle, significantly impairing work,
        education, and daily life.
            (3) Despite its prevalence and debilitating impact, PMDD
        remains under-diagnosed, under-researched, and stigmatized.
            (4) Early detection, effective treatment, and increased
        public and provider awareness are essential to improving
        quality of life for individuals living with PMDD.

SEC. 3. RESEARCH WITH RESPECT TO PREMENSTRUAL DYSPHORIC DISORDER
              (PMDD).

    (a) In General.--The Secretary of Health and Human Services (in
this section referred to as the ``Secretary''), acting through the
Director of the National Institutes of Health, shall--
            (1) expand and intensify research on Premenstrual Dysphoric
        Disorder (referred to in this section as ``PMDD''), including
        the causes, risk factors, diagnosis, and treatment of PMDD;
            (2) support clinical trials to develop improved treatment
        options for PMDD; and
            (3) ensure adequate representation of diverse racial,
        ethnic, and socioeconomic populations in PMDD-related research.
    (b) Surveillance and Data Collection.--The Secretary shall collect
and publish data on--
            (1) the prevalence and incidence of PMDD across
        populations;
            (2) the economic and workforce impact of PMDD; and
            (3) barriers to diagnosis and treatment of PMDD.
    (c) Authorization of Appropriations.--To carry out this section
there are authorized to be appropriated such sums as is necessary for
each of fiscal years 2027 through 2031.

SEC. 4. EDUCATION AND DISSEMINATION OF INFORMATION WITH RESPECT TO
              PREMENSTRUAL DYSPHORIC DISORDER (PMDD).

    (a) In General.--The Secretary shall carry out a public health
awareness campaign that is designed to--
            (1) raise patient and health care provider awareness of
        PMDD symptoms and treatment options;
            (2) reduce stigma associated with menstrual health
        conditions; and
            (3) encourage individuals to seek timely medical care.
    (b) Provider Education.--The Secretary, acting through the
Administrator of the Health Resources and Services Administration,
shall develop, and disseminate, continuing medical education materials
to ensure that health care providers have sufficient knowledge--
            (1) to accurately diagnose PMDD;
            (2) to distinguish PMDD from other mental health and
        gynecological conditions; and
            (3) to provide evidence-based care.
    (c) Coordination.--In carrying out this section, the Secretary
shall coordinate with existing awareness, education, and outreach
programs and activities of the Department of Health and Human Services.
    (d) Authorization of Appropriations.--To carry out this section
there are authorized to be appropriated such sums as is necessary for
each of fiscal years 2026 through 2030.

SEC. 5. GRANTS TO TRAIN HEALTH PROFESSIONALS WITH RESPECT TO PMDD.

    (b) In General.--The Secretary shall award grants to eligible
entities for the purpose described in subsection (b).
    (c) Use of Funds.--A grant awarded under this subsection shall be
used to develop, establish, or expand training programs (including
accredited residency programs, fellowships, or other related clinical
training) for physicians, registered nurses, nurse practitioners,
physician assistants, pharmacists, other health care providers, and
students and trainees to improve care, treatment, or management
services for PMDD.
    (d) Eligibility.--To be eligible to receive a grant under this
subsection, an entity shall--
            (1) be--
                    (A) an accredited school of medicine or osteopathic
                medicine;
                    (B) an accredited nursing school;
                    (C) an accredited school of pharmacy;
                    (D) an accredited public or nonprofit private
                hospital;
                    (E) an accredited medical residency program;
                    (F) an accredited nurse practitioner residency
                program; or
                    (G) a related training program for clinicians,
                allied health professionals, or social workers that
                interface with affected populations, which may include
                hospitals and research institutions, as determined by
                the Secretary; and
            (2) submit an application to the Secretary at such time, in
        such manner, and containing such information as the Secretary
        may require.
    (e) Training Opportunities.--In carrying out this section, the
Secretary shall expand outreach activities to support and expand
training programs, fellowships, and other opportunities for students,
faculty, and trainees (including continuing medical education) or
establish new training opportunities to address barriers to access to--
            (1) primary and specialty care services to support mid-life
        women's health; and
            (2) early detection, diagnosis, treatment, and care
        services for perimenopause, menopausal symptoms, and related
        chronic conditions.
    (f) Authorization of Appropriations.--To carry out this section
there are authorized to be appropriated such sums as is necessary for
each of fiscal years 2027 through 2031.

SEC. 6. REPORT ON IMPACTS ON PMDD RESEARCH AND TREATMENT.

    (a) Report.--Not later than 2 years after the date of the enactment
of this Act, the Secretary shall submit to Congress a report on
progress made in--
            (1) expanding PMDD research;
            (2) improving awareness of, and education on, PMDD; and
            (3) increasing access to diagnosis of, and treatment for,
        PMDD.
    (b) Authorization of Appropriations.--To carry out this section
there are authorized to be appropriated such sums as is necessary for
each of fiscal years 2027 through 2031.
                                 <all>